Physician profile
Qiangjun Cai
NPI 1972763159
$1,217.91
in general payments reported to CMS, 2019-2025
11 companies · $62.43 in 2025
The $62.43 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $145 · 2021: $308 · 2022: $247 · 2023: $111 · 2024: $176 · 2025: $62.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $330 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $330.24 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $205.50 | 2022-2025 | Advisor |
| Vifor Pharma, INC. | $200.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $167.90 | 2019-2020 | |
| Amgen INC. | $158.22 | 2019-2024 | Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.31 | 2021-2023 | Xifaxan |
| Boston Scientific Corporation | $130.02 | 2023-2025 | Bodyguardian |
| Biotronik INC. | $99.65 | 2019 | |
| Janssen Biotech, INC. | $53.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
| Preventice Services, LLC | $14.39 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qiangjun Cai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.